Laura Carelli1, Federica Solca2, Simone Migliore3, Silvia Torre1, Agostino Brugnera4, Francesca Mancini1, Sofia Tagini1, Roberta Ferrucci5,6,7, Sabrina Maffi3, Consuelo Ceccarelli8, Jacopo Pasquini2, Jenny Sassone9,10, Ferdinando Squitieri3, Andrea Ciammola11, Vincenzo Silani1,2, Barbara Poletti12. 1. Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy. 2. Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, University of Milan, Milan, Italy. 3. Huntington and Rare Diseases Unit, Fondazione IRCCS Casa Sollievo Della Sofferenza Research Hospital, San Giovanni Rotondo, Italy. 4. Department of Human and Social Sciences, University of Bergamo, Bergamo, Italy. 5. Aldo Ravelli Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, International Medical School, University of Milan, Milan, Italy. 6. ASST Santi Paolo e Carlo, Neurology Clinic III, Milan, Italy. 7. IRCCS Ca' Granda Foundation Maggiore Policlinico Hospital, Milan, Italy. 8. Italian League for Research on Huntington Disease (LIRH) Foundation, Rome, Italy. 9. Vita-Salute San Raffaele University, Milan, Italy. 10. Division of Neuroscience San Raffaele Scientific Institute, Milan, Italy. 11. Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy. a.ciammola@auxologico.it. 12. Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy. b.poletti@auxologico.it.
Abstract
INTRODUCTION: The study aims at investigating psychometric properties of the Edinburgh cognitive and behavioural ALS screen (ECAS) in Parkinson's (PD) and Huntington's (HD) diseases. The sensitivity and specificity of the ECAS in highlighting HD and PD cognitive-behavioural features and in differentiating between these two populations and from healthy controls (HC) were evaluated. Moreover, correlations between the ECAS and traditional cognitive measures, together with core clinical features, were analysed. METHODS: Seventy-three PD patients, 38 HD patients, and 49 education-matched healthy participants were enrolled. Participants were administered the ECAS, together with other cognitive screening tools and psychological questionnaires. Patients' behavioural assessment was also carried out with carers. RESULTS: The ECAS distinguished between HD patients and HC and between the two clinical syndromes with high sensitivity and specificity. Even if the diagnostic accuracy of the ECAS in distinguishing between PD and HC was low, the PD cognitive phenotype was very well described by the ECAS performances. Convergent validity of the ECAS against other traditional cognitive screening was observed, as well as correlations with psychological aspects and typical clinical features, especially for the HD group. CONCLUSIONS: The ECAS represents a rapid and feasible tool, useful also in other neurodegenerative disorders affecting verbal-motor abilities than the amyotrophic lateral sclerosis such as PD and HD. Clinical applications in these neurodegenerative conditions require further investigations and, probably, some adaptations of the original test.
INTRODUCTION: The study aims at investigating psychometric properties of the Edinburgh cognitive and behavioural ALS screen (ECAS) in Parkinson's (PD) and Huntington's (HD) diseases. The sensitivity and specificity of the ECAS in highlighting HD and PD cognitive-behavioural features and in differentiating between these two populations and from healthy controls (HC) were evaluated. Moreover, correlations between the ECAS and traditional cognitive measures, together with core clinical features, were analysed. METHODS: Seventy-three PD patients, 38 HD patients, and 49 education-matched healthy participants were enrolled. Participants were administered the ECAS, together with other cognitive screening tools and psychological questionnaires. Patients' behavioural assessment was also carried out with carers. RESULTS: The ECAS distinguished between HD patients and HC and between the two clinical syndromes with high sensitivity and specificity. Even if the diagnostic accuracy of the ECAS in distinguishing between PD and HC was low, the PD cognitive phenotype was very well described by the ECAS performances. Convergent validity of the ECAS against other traditional cognitive screening was observed, as well as correlations with psychological aspects and typical clinical features, especially for the HD group. CONCLUSIONS: The ECAS represents a rapid and feasible tool, useful also in other neurodegenerative disorders affecting verbal-motor abilities than the amyotrophic lateral sclerosis such as PD and HD. Clinical applications in these neurodegenerative conditions require further investigations and, probably, some adaptations of the original test.
Authors: Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre Journal: Mov Disord Date: 2012-01-24 Impact factor: 10.338
Authors: A Alberici; C Geroldi; M Cotelli; A Adorni; M Calabria; G Rossi; B Borroni; A Padovani; O Zanetti; A Kertesz Journal: Neurol Sci Date: 2007-04 Impact factor: 3.307
Authors: Katya Rascovsky; John R Hodges; David Knopman; Mario F Mendez; Joel H Kramer; John Neuhaus; John C van Swieten; Harro Seelaar; Elise G P Dopper; Chiadi U Onyike; Argye E Hillis; Keith A Josephs; Bradley F Boeve; Andrew Kertesz; William W Seeley; Katherine P Rankin; Julene K Johnson; Maria-Luisa Gorno-Tempini; Howard Rosen; Caroline E Prioleau-Latham; Albert Lee; Christopher M Kipps; Patricia Lillo; Olivier Piguet; Jonathan D Rohrer; Martin N Rossor; Jason D Warren; Nick C Fox; Douglas Galasko; David P Salmon; Sandra E Black; Marsel Mesulam; Sandra Weintraub; Brad C Dickerson; Janine Diehl-Schmid; Florence Pasquier; Vincent Deramecourt; Florence Lebert; Yolande Pijnenburg; Tiffany W Chow; Facundo Manes; Jordan Grafman; Stefano F Cappa; Morris Freedman; Murray Grossman; Bruce L Miller Journal: Brain Date: 2011-08-02 Impact factor: 13.501
Authors: Rachael A Lawson; Alison J Yarnall; Gordon W Duncan; Tien K Khoo; David P Breen; Roger A Barker; Daniel Collerton; John-Paul Taylor; David J Burn Journal: Parkinsonism Relat Disord Date: 2014-07-18 Impact factor: 4.891